染色体微阵列分析在产前诊断中的应用指南(2023)
本指南由全国产前诊断专家组牵头、北京协和医院等机构参与修订,针对CMA技术产前诊断应用的临床指征、质量控制、数据分析解读、报告撰写及检测前后遗传咨询等关键环节进行规范阐述。
要点
- CMA已成为针对胎儿染色体拷贝数缺失或重复异常的一线产前诊断技术。
- 指南涵盖临床应用指征、检测质量控制、数据分析解读、诊断报告撰写及检测前后遗传咨询。
- 指南由国家卫生健康委员会妇幼健康司批准的全国产前诊断专家组牵头制定。
核心结论
- 本指南旨在推动全国胎儿染色体及基因组疾病产前诊断工作的规范性和先进性得到进一步提升。
研究设计与样本
- 由国家卫生健康委员会妇幼健康司批准成立的全国产前诊断专家组牵头,委托北京协和医院等数家产前诊断机构撰写初稿,经专家组全体专家研讨、审查反馈及广泛函审修改后最终形成。
主要发现
- 2014年第1版专家共识发布后经过8年余临床和技术发展,CMA技术已成为针对胎儿染色体拷贝数缺失或重复异常的一线产前诊断技术,广泛应用于我国产前诊断领域。
- 随着行业发展和诊断经验积累,CMA技术在临床诊断指征、数据分析和检测前后遗传咨询等许多重要方面亟须进一步规范和提升,以使应用更加符合临床需求。
关键数值与推荐
- 指南针对CMA技术产前诊断应用的临床应用指征、检测质量控制、数据分析解读、诊断报告撰写、检测前后遗传咨询等工作规范进行了详细阐述和介绍。
临床怎么用
- 本指南完整体现了当前中国专家团队对CMA技术产前诊断应用的经验集成、专业思考和指导意见,用于规范产前诊断中CMA技术的临床应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After the promulgation of the first edition of expert consensus on the application of chromosomal microarray analysis (CMA) technology in prenatal diagnosis in 2014, after 8 years of clinical and technical development, CMA technology has become a first-line diagnosis technology for fetal chromosome copy number deletion or duplication abnormalities, and is widely used in the field of prenatal diagnosis in China. However, with the development of the industry and the accumulation of experience in case diagnosis, the application of CMA technology in many important aspects of prenatal diagnosis, such as clinical diagnosis testimony, data analysis and genetic counseling before and after testing, needs to be further standardized and improved, so as to make the application of CMA technology more in line with clinical needs. The revision of the guideline was led by the National Prenatal Diagnostic Technical Expert Group, and several prenatal diagnostic institutions such as Peking Union Medical College Hospital were commissioned to write, discuss and revise the first draft, which was discussed and reviewed by all the experts of the National Prenatal Diagnostic Technical Expert Group, and was finally formed after extensive review and revision. This guideline is aimed at the important aspects of the application of CMA technology in prenatal diagnosis and clinical diagnosis, from the clinical application of evidence, test quality control, data analysis and interpretation, diagnosis report writing, genetic counseling before and after testing and other work specifications are elaborated and introduced in detail. It fully reflects the integrated experience, professional thinking and guidance of the current Chinese expert team on the prenatal diagnosis application of CMA technology. The compilation of the guideline for the application of CMA technology in prenatal diagnosis will strive to promote the standardization and advancement of prenatal diagnosis of fetal chromosome diseases in China. 2014年我国第1版关于染色体微阵列分析(CMA)技术应用于产前诊断的专家共识发布后,经过8年余临床和技术发展的推动,CMA技术目前已经成为针对胎儿的染色体拷贝数缺失或重复异常的一线产前诊断技术,广泛应用于我国产前诊断领域。但随着行业的发展和诊断经验的积累,CMA技术临床应用的许多重要方面,如临床诊断指征、数据分析和检测前后遗传咨询等亟须进一步规范和提升,以使CMA技术的产前诊断应用更加符合临床的需求。本次修订工作由国家卫生健康委员会妇幼健康司批准成立的全国产前诊断专家组牵头,委托北京协和医院等数家产前诊断机构进行初稿的撰写和讨论修订,并经全国产前诊断专家组全体专家进行研讨和审查反馈,以及广泛函审修改后最终形成本指南。本指南针对CMA技术在产前诊断临床应用的重要方面,包括临床应用指征、检测的质量控制、数据的分析解读、诊断报告撰写、检测前后遗传咨询等工作的规范开展进行了详细的阐述和介绍,完整体现了当前中国专家团队对于CMA技术产前诊断应用的经验集成、专业思考和指导意见。本指南的编制将推动全国胎儿染色体及基因组疾病产前诊断工作的规范性和先进性得到进一步的提升。.
引用
- [Guideline for the application of chromosomal microarray analysis in prenatal diagnosis (2023)]. Zhonghua Fu Chan Ke Za Zhi. 2023. PMID: 37599253. doi:10.3760/cma.j.cn112141-20230327-00146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。